General Information
Tapinarof API is a novel, first-in-class, small molecule nonsteroidal, therapeutic aryl hydrocarbon receptor (AhR) agonist compound that acts as an anti-inflammatory and immunomodulatory agent. It is indicated for the treatment of plaque psoriasis in adults, in its finished dose. This novel therapeutic has also been shown to be effective for atopic dermatitis and is currently in phase 3 for this indication. Tapinarof works by regulating the activity of immune cells, reducing inflammation, and promoting the repair and regeneration of damaged skin cells. It received initial approval from the FDA in 2022.
About the API
Systematic name
2-(1-Methylethyl)-5-[(1E)-2-phenylethenyl]-1,3-benzenediol
Trade name(s)
Vtama
Technology
Synthetic
Molecular Formula
C17H18O2
Molecular Weight
254.32 g/mol
Therapeutic category
Dermatology
Available formulations
Topical / Dermatological